Lipoprotein(a), or Lp(a), is an inherited, largely stable lipid particle that can increase cardiovascular risk beyond what is captured by a standard lipid panel.
In modern preventive cardiology, it is best viewed as a risk-enhancing factor that can help refine treatment decisions, especially in patients with premature or unexplained ASCVD.
What Lp(a) is
Lp(a) is structurally similar to LDL but contains an added apolipoprotein(a) component attached to apoB-100. This unique structure appears to contribute to atherogenic, inflammatory, and possibly prothrombotic effects.
Unlike LDL-C, Lp(a) is determined mainly by genetics and is usually established early in life, remaining relatively constant over time.
Why it matters
Elevated Lp(a) is associated with myocardial infarction, stroke, peripheral arterial disease, and calcific aortic valve disease.
Risk becomes especially relevant when Lp(a) is elevated in a patient who otherwise appears to have acceptable LDL-C control.
In that setting, Lp(a) may explain residual risk and support a more intensive prevention strategy.
Who should be tested
Lp(a) measurement is particularly useful in patients with a family history of premature ASCVD, personal premature ASCVD, familial hypercholesterolemia, or a family history of elevated Lp(a).
The 2026 ACC/AHA Dyslipidemia Guideline strongly recommends universal screening of adults for elevated Lp(a), with special considerations for children under 18.
Because levels are generally stable, repeat testing is usually not needed unless there is a specific clinical reason.
How to interpret results
A commonly used threshold for elevated Lp(a) is 125 nmol/L, or 50 mg/dL.
At or above this level, Lp(a) is considered a cardiovascular risk-enhancing factor.
The key clinical point is not just the number itself, but how it changes overall risk assessment and treatment intensity.
Current management
There is no widely approved, outcome-proven therapy that specifically eliminates Lp(a) risk.
Therefore, management focuses on aggressive control of modifiable factors, especially LDL-C reduction, blood pressure control, diabetes management, weight optimization, and tobacco cessation.
Statins remain foundational for ASCVD prevention, even though they do not lower Lp(a), and PCSK9 inhibitors may modestly reduce Lp(a) while improving overall risk.
Emerging therapies
The field is moving quickly. Several RNA-targeting therapies are in late-stage clinical trials, including pelacarsen, olpasiran, and lepodisiran, with additional agents such as zerlasiran and muvalaplin in development.
These studies are important because they may finally answer the central question: does directly lowering Lp(a) reduce cardiovascular events?
Clinical takeaway
Lp(a) should be treated as a marker of inherited risk, not a curiosity on a lipid report.
For patients with elevated Lp(a), the practical response is to intensify overall cardiovascular prevention and use shared decision-making to explain why the risk is higher even when LDL-C looks controlled.
That approach helps personalize care while we await definitive outcome data for Lp(a)-specific therapies.
References
American Heart Association. Lipoprotein(a) information pageAHA-Lpa-Toolkit.pdf
American Heart Association. Cholesterol overviewAHA-Lpa-Toolkit.pdf
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423ahajournals
National Lipid Association. 2026 ACC/AHA Multisociety Dyslipidemia Guideline Releasedlipid
Reyes-Soffer G, et al. Lp(a) AHA Scientific StatementAHA-Lpa-Toolkit.pdf
Wilson DP, et al. NLA Statement on Lp(a)AHA-Lpa-Toolkit.pdf
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.